Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:55 PM
Ignite Modification Date:
2025-12-24 @ 7:55 PM
NCT ID:
NCT05036304
Eligibility Criteria:
Inclusion Criteria:
1. achieve a score ≥18/30 and ≤24/30 on the Montreal Cognitive Assessment
2. have subjective cognitive impairment based on interview
3. have no significant impairment in daily function, as determined by a score ≥6/8 on the Lawton and Brody Instrumental Activities of Daily Living Scale
4. no diagnosis of dementia
5. aged 65 to 80 years old
6. live independently in their own home
7. live in the Greater Vancouver area
8. read, write, and speak English with acceptable visual and auditory acuity
9. are cleared to start a supervised exercise programme based on the Physical Activity Readiness Questionnaire for Everyone
10. able to walk independently
11. able to provide informed consent
Exclusion Criteria:
1. participating in regular moderate to vigorous intensity aerobic exercise in the last 3 months
2. planning to enroll in a concurrent exercise or drug trial targeting cognitive function
3. diagnosed with a neurological, cerebrovascular, or psychiatric disease, or other chronic medical condition requiring intensive treatment and monitoring
4. have major impairments in eyesight, hearing or motor movements
5. have clinically significant neuropathy or musculoskeletal or joint disease
6. have a recent traumatic brain injury, including concussions
7. are currently using prescribed cognitive intervention or electromagnetic stimulation
8. at the time of recruit, indicate they recently (within the last 2 months) or will start taking drugs that significantly alter cognition, movement, or affect, such as cholinesterase inhibitors, anticholinergics, hormone replacement therapy, or antidepressants
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
65 Years
Maximum Age:
80 Years
Study:
NCT05036304
Study Brief:
Protocol Section:
NCT05036304